Volume 3(1); Pages: 53-60, 2023 | DOI: 10.21873/cdp.10179

Relationship Between TTF-1 Expression and PFS of Pemetrexed-containing Chemotherapy in Non-squamous-NSCLC Patients With and Without Driver Genes

SHINICHIRO OKAUCHI, KUNIHIKO MIYAZAKI, TOSHIHIRO SHIOZAWA, HIROAKI SATOH, NOBUYUKI HIZAWA

Abstract

Background/Aim: We performed a retrospective study too clarify whether the presence or absence of driver genes affects the relationship between thyroid transcription factor-1 (TTF-1) expression and response to pemetrexed (PEM) in non-squamous non-small cell lung cancer (non-sq-NSCLC) patients. Patients and Methods: We reviewed the medical charts of patients treated with PEM-containing chemotherapy during the period from February 2016 to February 2022 at Mito Medical Center-University of Tsukuba, Ryugasaki Saiseikai General Hospital, and University of Tsukuba Hospital. Results: During the period of the study, 185 driver gene-negative patients negative, and 65 driver gene-positive patients were evaluated. Among the 165 driver gene-negative patients, progression free survival (PFS) of TTF-1-expressing patients treated with PEM-containing chemotherapy was significantly longer compared to that of TTF-1-negative patients. In the analysis of 65 driver gene-positive patients, the PFS of TTF-1-positive patients treated with PEM-containing chemotherapy did not differ significantly from that of TTF-1-negative patients. There was no significant difference in PFS between driver gene-negative and driver gene-positive patients treated with PEM-containing chemotherapy. Comparison between four groups defined according to the presence of driver gene and TTF-1 expression indicated shorter PFS only in ‘driver gene-negative and TTF-1-negative’ patients. Conclusion: In driver gene-positive non-sq NSCLC patients, expression of TTF does not affect the survival outcome of PEM-containing-chemotherapy. In other words, in these patients, second-line or later-line PEM-containing chemotherapy after development of resistance for specific-tyrosine kinase inhibitor could be expected to have the same level of efficacy as first-line PEM containing chemotherapy in driver gene-negative, TTF-1-positive non-sq NSCLC patients.

Thyroid transcription factor-1 (TTF-1) is expressed in thyroid follicle, parathyroid gland, alveolar epithelium, and diencephalon, and participates in the differentiation, development, and functional maintenance of these organs (1-3). A number of studies have shown that TTF-1 expression is associated with improved survival in patients with advanced non-squamous non-small cell lung cancer (non-sq-NSCLC) (4-6). More interesting, expression of TTF-1 has been shown to be associated with the efficacy of several antitumor drugs and progression-free survival (PFS) (7-15). Of note, non-sq-NSCLC patients with TTF-1 expression have been shown to have a better prognosis than those without expression, responding to pemetrexed (PEM)-containing chemotherapy (7-15). Due to its high response rate and low incidence of serious side effects, PEM has become one of the essential antineoplastic agents for non-sq-NSCLC in routine clinical practice (7-15). Some of these previous studies examined the correlation between the expression of TTF-1 and PFS of patients treated with PEM-containing chemotherapy including non-sq NSCLC patients with driver mutations, such as epidermal growth factor receptor (EGFR) mutation (8, 10-12, 14, 15). However, none of them analyzed the association between TTF-1 expression and PEM response considering the presence or absence of the driver gene. Driver gene-positive NSCLC, such as those carrying an EGFR mutation or an ALK rearrangement, can be treated with specific responsive tyrosine kinase inhibitors (TKIs). In such driver gene-positive patients, TKIs are prescribed as the first-line therapy. Therefore, the treatment sequence for these patients is clearly different from that for patients with driver gene-negative NSCLC. It is also unclear how the presence or absence of the driver gene is related to response to PEM-containing chemotherapy.

Therefore, we conducted this study to clarify whether the presence or absence of the driver gene affects the relationship between TTF-1 expression and response to PEM in non-sq-NSCLC patients.

Patients and Methods

This study examined the medical records of all patients diagnosed with NSCLC between April 2009 and June 2022 at three tertiary hospitals: Mito Medical Center, University of Tsukuba, Ryugasaki Saiseikai General Hospital, and University of Tsukuba Hospital. NSCLC was pathologically diagnosed using the World Health Organization classification with tumor node metastasis staging (TNM Classification, eighth Edition) (16). Staging was performed from computed tomography/magnetic resonance imaging of the head, ultrasonography/computed tomography of the abdomen, and bone scans. Patient demographics including age, sex, histopathology, disease stage and survival were extracted from their medical records. We confirmed the presence or absence of driver genes. The study included patients with non-sq-NSCLC receiving first-line or later lines of PEM-containing chemotherapy.

Expression of TTF-1 was assessed by immunohistochemical staining using a rabbit monoclonal antibody (1:250; Abcam, Cambridge, UK). We evaluated the degree of positivity as follows: negative (-, 0%); very focally positive (+, 25% in hot spots); focally positive (++, 50% in hot spots); diffusely positive (+++, >50% and a uniform pattern). In this study, only ‘diffusely positive’ were treated as TTF-1-positive.

Statistical analysis. Nominal variables were compared using a chi-squared test and values with an unknown population variance were compared using a nonparametric Mann-Whitney test. PFS was defined as the period from randomization to disease progression or death from any cause. PFS was calculated with a Kaplan-Meier analysis and compared using a log-rank test. Cox proportional hazards modeling with the forward-backward stepwise method was used to identify the independent variables to be included in the final model, with PFS as the dependent variable. Multivariable analyses included only variables with a p-value of less than 0.1 in univariate analysis. All statistical analyses were conducted using SPSS version 23 (IBM Corporation, Armonk, NY, USA). A p-value of less than 0.05 was considered significant.

Ethics. This study complied with the Ethical Guidelines for Clinical Studies issued by the Ministry of Health, Labor, and Welfare of Japan. Written informed consent to participate in a non-interventional retrospective study was obtained from each patient. The Mito Medical Center-University of Tsukuba Hospital Ethics Committee approved the examination of medical records for the purpose of this study.

Results

Clinicopathological features of the patients. Figure 1 shows the study flow chart. During the study period, 1,203 non-sq-NSCLC patients were diagnosed. Among them, 339 patients were treated with PEM-containing chemotherapy. Of these, 250 patients underwent TTF-1 immunostaining before treatment. Of the 250 patients, 185 were negative for any driver gene, and 65 were positive for a driver gene (54 EGFR gene positive, 11 other driver gene positive). Table I shows the clinicopathological features of TTF-1-positive and -negative driver gene-negative patients. There were 185 driver gene-negative patients, which were treated with PEM-containing chemotherapy. Among the 185driver gene-negative patients with non-sq NSCLC, 98 (53.0%) were TTF-1 positive. Fifty-three (81.5%) of 65 driver gene-positive patients were TTF-1 positive: 42 (77.8%) of 54 EGFR-positive patients and all six patients carrying the ALK rearrangement were TTF-1 positive.

Figure 1. Flowchart of patient selection.

In this study, we designated ‘driver gene- negative-TTF-1 positive patient group’, ‘driver gene- negative-TTF-1 negative patient group’, ‘driver gene- positive-TTF-1 positive patient group’, and ‘driver gene- positive-TTF-1 negative patient group’ as Group A, Group B, Group C, and Group D, respectively.

Comparison of PFS between driver dene negative patients with or without TTF-1. We first compared the clinicopathological features of Group A and Group B patients. As shown in Table I there was no statistically significant difference between them, so we compared PFS of these groups. Figure 2A shows the Kaplan-Meier curves of these two groups of patients. PFS of Group A patients was significantly longer than that of Group B patients (p=0.001) (median PFS: 9.0 and 4.0 months). In the uni- and multivariate analyses, TTF-1 positivity was confirmed to be a significant favorable factor in patients with driver gene-negative non-sq NSCLC (Table II).

Figure 2. Kaplan-Meier curves of group A and group B patients. Progression-free survival (PFS) of Group A patients was significantly longer than that of Group B patients (p=0.001) (median PFS: 9.0 and 4.0 months) (A). Kaplan-Meier curves of PFS in driver gene-positive patients with or without TTF-1. There was no statistically significant difference in PFS between Group C and Group D patients (p=0.2805) (B).

Comparison of PFS between driver gene- positive patients with or without TTF-1. Table II shows the clinicopathological features of Group C and Group D patients. We confirmed that there was no significant difference in the features of these patients, and then compared PFS between driver gene positive patients with or without TTF-1. As shown in Figure 2B, there was no statistically significant difference in PFS between Group C and Group D patients (p=0.2805) (median PFS: 7.0 and 5.0 months). In 54 EGFR-positive patients, there was no statistically significant difference in PFS between TTF-1-positive and -negative patients (p=0.6139) (median PFS: 5.0 and 4.5 months). In univariate analyses, none of the factors favored PFS in patients with driver gene-positive non-sq NSCLC (Table II).

Comparison of PFS between driver gene- positive and negative patients with or without TTF-1. Table III shows the clinicopathological features of driver gene-negative (Group A and B) and driver gene-positive patients (Group C and D). There was no significant difference in the features of these patients except for sex and TTF-1. As ‘sex was not a factor affecting PFS in neither the driver gene-negative group nor the driver gene-positive group (Table II), we compared PFS of driver gene-negative patients with that of driver gene-positive patients. As shown in Figure 3A, there was no significant difference between these two groups (p=0.9955). No significant difference in PFS was observed between Groups A, B and C (p=0.1185). However, a statistically significant difference in PFS was confirmed between ‘Group A+Group B+Group C’ and Group D (p=0.001) (Figure 3B).

Figure 3. Kaplan-Meier curves of progression-free survival (PFS) in driver-gene negative (group A and group B patients) and driver-gene positive patients (group C and group D patients). There was no significant difference between these two groups (p=0.9955) (A). Kaplan-Meier curves of PFS between ‘Group A+Group B+Group C’ and Group D. There was no statistically significant difference between them (p=0.001) (median PFS:8.0 and 4.0 months) (B).

Discussion

In this study, the following four results were obtained. First, in 165 driver gene-negative patients, the PFS of TTF-1-expressing patients treated with PEM-containing chemotherapy was significantly longer than that of TTF-1-negative patients, as observed in previous reports (7-15). In uni- and multivariate analysis, the expression of TTF-1 was confirmed as a significant favorable factor for PFS of patients treated with PEM-containing chemotherapy. Second, however, in 65 driver gene-positive patients, PFS of those treated with PEM-containing chemotherapy was not significantly different from that of TTF-1-negative patients. In 54 EGFR-positive patients, the PFS of TTF-1-positive patients treated with PEM-containing chemotherapy was not significantly different from that of TTF-1-negative patients. Third, there was no significant difference in PFS following treatment with PEM-containing chemotherapy between driver gene-negative and driver gene-positive patients. Fourth, the comparison of PFS of patients treated with PEM-containing chemotherapy and grouped according to the presence of driver gene and expression of TTF-1indicated that PFS was shorter in ‘driver gene-negative and TTF-1-negative’ patients.

Table IV shows the driver gene and positivity for TTF-1 in previous studies (8, 10, 11, 13, 14, 17-27). The positivity rates varied since the TTF-1 antibody used and the threshold for positive staining were different in each study, but the positive rate in driver gene-negative patients is generally lower than that in driver gene-positive patients (8, 10, 11, 13, 14, 17-27). This result is consistent with our present study. Regarding driver gene-positive patients, the TTF-1 expression was evaluated only in patients with EGFR mutation and those carrying the ALK rearrangement as shown in Table IV. To the best of our knowledge, there is no study on TTF-1 expression in patients with other driver genes than EGFR mutation and ALK rearrangement. Some studies have investigated the relationship between TTF-1 expression and PEM-containing chemotherapy in driver gene-negative patients, but no study examined this relationship in driver gene-positive patients.

In our analysis of 65 driver gene-positive patients (54 of whom were EGFR mutation-positive), no significant difference was found in PFS between TTF-1-positive (median PFS: 7.0 months) and TTF-1-negative patients (median PFS: 5.0 months) treated with PEM-containing chemotherapy. In a review by Han et al., the median PFS of patients treated with PEM-containing chemotherapy after EGFR-TKI failure was 5.09 months (28). Kaneda et al. reported that in first-line cisplatin plus PEM treatment of 78 EGFR-positive patients, the median PFS in the group carrying the L858R mutation and the group with Ex 19 del was 9.4 and 5.5 months, respectively (29). Considering these research results, PFS of patients treated with PEM-containing chemotherapy is considered to reflect real clinical practice. In addition, median PFS of driver gene-negative and driver gene-positive patients treated with PEM-containing chemotherapy was 6.0 and 6.0 months, respectively, and there was no significant difference between them. PEM has often been administered as first-line therapy in driver gene-negative patients, but it is also prescribed as second-line or later therapy in driver gene-positive patients. Even after driver-gene-specific TKI therapy, the efficacy of PEM-containing chemotherapy in patients with driver gene-positive non-sq NSCLC might be as good as that given as first-line to patients with driver gene-negative non-sq NSCLC.

TTF-1 has been associated with PFS of driver gene-negative patients treated with PEM-containing chemotherapy, but not in driver gene-positive patients. The reason for this difference is not clear. In our study, there was no statistically significant difference in PFS among Groups A, C, and D. There was a significant difference in PFS between these three groups and the driver gene-negative-TTF-1-negative group (Group B). Considering these results together, it is inferred that only Group B shows poor PFS following PEM-containing chemotherapy. In relation to poor PFS in driver gene-negative TTF-1 negative non-sq NSCLC patients, there are some interesting reports (30, 31). Tanaka et al. reported that sergycin, a chondroitin sulfate proteoglycan, played a pivotal role in tumor-stromal interaction and reprogramming into an aggressive and immunosuppressive tumor microenvironment in TTF-1-negative lung adenocarcinoma (30). In a report by Matsubara et al., immunohistological expression of TFF-1 correlated with tumor spread through air spaces in the lung cancer lesion, and a poor prognosis in advanced stages (31). However, the mechanism is still unknown.

This study had some limitations. First, although there was no intentional selection bias, it must be pointed out that these were the results of the analysis of the data of patients who were evaluated for TTF-1, and not the results of all patients during the study period. Although patients from three institutions were collected the number is small and the study retrospective. Due to the relationship between the time when this study was conducted and when the driver gene tests became available, it is possible that we were not able to identify driver gene-positive patients other than those carrying the EGFR mutation or the ALK rearrangement. In TTF-1 immunohistochemical staining, only “uniform pattern of 50% or more” was regarded as “positive” in this study. This might have influenced the results. It is hypothesized that overall survival might differ between driver gene-positive and -negative patients due to differences in TTF-1, but this study did not analyze overall survival. Based on these limitations, it is expected that further studies will be conducted to confirm and expand our results.

Conclusion

In driver gene-positive non-sq NSLC patients, the presence or absence of TTF-1 was found to have little effect on the response to PEM-containing chemotherapy. In driver gene-positive non-sq NSLC patients, even second-line or later treatment after specific-TKI treatment, PEM-containing chemotherapy could be expected to have the same level of efficacy as first-line PEM-containing chemotherapy in driver gene-negative-TTF-1-positive patients. Regarding PEM-containing chemotherapy in driver-gene positive non-sq NSCLC patients, a similar effect could be expected regardless of the expression of TTF-1.

Conflicts of Interest

The Authors have no conflicts of interest to declare in relation to this study.

Authors’ Contributions

SO and HS contributed to the planning, and OS, MK, ST and HS collected data. SO and KM conducted the design and acquisition of data and drafting the manuscript. HS and NH supervised the manuscript. All Authors read and approved the final manuscript.

References

1. Civitareale D, Lonigro R, Sinclair AJ and Di Lauro R: A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J 8(9): 2537-2542, 1989. PMID: 2583123. DOI: 10.1002/j.1460-2075.1989.tb08391.x
2. Lazzaro D, Price M, de Felice M and Di Lauro R: The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 113(4): 1093-1104, 1991. PMID: 1811929. DOI: 10.1242/dev.113.4.1093
3. Bohinski RJ, Di Lauro R and Whitsett JA: The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 14(9): 5671-5681, 1994. PMID: 8065304. DOI: 10.1128/mcb.14.9.5671-5681.1994
4. Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein LA, Ginsburg ME, Steinglass KM and Powell CA: Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101(7): 1632-1638, 2004. PMID: 15378500. DOI: 10.1002/cncr.20542
5. Chung KP, Huang YT, Chang YL, Yu CJ, Yang CH, Chang YC, Shih JY and Yang PC: Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest 141(2): 420-428, 2012. PMID: 21799026. DOI: 10.1378/chest.10-3149
6. Doherty MK, O’Connor E, Hannon D, O’Reilly A, Yen D, Redmond M, Grogan LM, Hennessy BT, Breathnach OS and Morris PG: Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy. Ir J Med Sci 188(1): 69-74, 2019. PMID: 29948461. DOI: 10.1007/s11845-018-1839-5
7. Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT and Scott H: Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol 8(10): 1255-1264, 2013. PMID: 24457236. DOI: 10.1097/JTO.0b013e3182a406a3
8. Elsamany SA, Al-Fayea TM, Alzahrani AS, Abozeed WN, Darwish W, Farooq MU, Almadani AS and Bukhari EA: Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome. Asian Pac J Cancer Prev 16(7): 2987-2991, 2015. PMID: 25854394. DOI: 10.7314/apjcp.2015.16.7.2987
9. Shiran I, Heller E, Jessel S, Kamer I, Daniel-Meshulam I, Navon R, Urban D, Onn A and Bar J: Non-small-cell lung cancer patients with adenocarcinoma morphology have a better outcome compared with patients diagnosed with non-small-cell lung cancer favor adenocarcinoma. Clin Lung Cancer 18(3): 316-323.e1, 2017. PMID: 28237243. DOI: 10.1016/j.cllc.2017.01.009
10. Schilsky JB, Ni A, Ahn L, Datta S, Travis WD, Kris MG, Chaft JE, Rekhtman N and Hellmann MD: Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer 108: 205-211, 2017. PMID: 28625636. DOI: 10.1016/j.lungcan.2017.03.015
11. Jie-Liu, Li XY, Zhao YQ, Liu RQ, Zhang JB, Ma J, Chen LJ and Hu XF: Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations. Pathol Res Pract 210(3): 176-181, 2014. PMID: 24370340. DOI: 10.1016/j.prp.2013.11.013
12. Frost N, Zhamurashvili T, von Laffert M, Klauschen F, Ruwwe-Glösenkamp C, Raspe M, Brunn M, Ochsenreither S, Temmesfeld-Wollbrück B, Suttorp N, Grohé C and Witzenrath M: Pemetrexed-based chemotherapy is inferior to pemetrexed-free regimens in thyroid transcription factor 1 (TTF-1)-negative, EGFR/ALK-negative lung adenocarcinoma: a propensity score matched pairs analysis. Clin Lung Cancer 21(6): e607-e621, 2020. PMID: 32620471. DOI: 10.1016/j.cllc.2020.05.014
13. Takeuchi A, Oguri T, Yamashita Y, Sone K, Fukuda S, Takakuwa O, Uemura T, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y and Niimi A: TTF-1 expression predicts the merit of additional antiangiogenic treatment in non-squamous non-small cell lung cancer. Anticancer Res 38(9): 5489-5495, 2018. PMID: 30194207. DOI: 10.21873/anticanres.12882
14. Park JY, Jang SH, Kim HI, Kim JH, Park S, Hwang YI, Jung KS, Seo J, Lee CY, Ko Y and Park YB: Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. BMC Cancer 19(1): 574, 2019. PMID: 31196060. DOI: 10.1186/s12885-019-5792-0
15. Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I and Meydan N: The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Cancer Res Ther 16(4): 737-744, 2020. PMID: 32930112. DOI: 10.4103/jcrt.JCRT_1404_16
16. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions and International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1): 39-51, 2016. PMID: 26762738. DOI: 10.1016/j.jtho.2015.09.009
17. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS and Chung JH: High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7(2): 323-330, 2012. PMID: 22237264. DOI: 10.1097/JTO.0b013e3182381515
18. Vallee A, Sagan C, Le Loupp AG, Bach K, Dejoie T and Denis MG: Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol 43(4): 1045-1051, 2013. PMID: 23934203. DOI: 10.3892/ijo.2013.2056
19. Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C, Rieker RJ, Hartmann A, Ruemmele P and Dietmaier W: EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 109(7): 1821-1828, 2013. PMID: 24002608. DOI: 10.1038/bjc.2013.511
20. Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA, Schirmacher P, Hoffmann H, Muley T and Weichert W: EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J 43(3): 872-883, 2014. PMID: 23988776. DOI: 10.1183/09031936.00018013
21. Shanzhi W, Yiping H, Ling H, Jianming Z and Qiang L: The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One 9(4): e95479, 2014. PMID: 24743427. DOI: 10.1371/journal.pone.0095479
22. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P and Simon GR: Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience 1(8): 522-528, 2014. PMID: 25594059. DOI: 10.18632/oncoscience.72
23. Zhao Q, Xu S, Liu J, Li Y, Fan Y, Shi T, Wei S, Tang SC, Liu H and Chen J: Thyroid transcription factor-1 expression is significantly associated with mutations in exon 21 of the epidermal growth factor receptor gene in Chinese patients with lung adenocarcinoma. Onco Targets Ther 8: 2469-2478, 2015. PMID: 26388694. DOI: 10.2147/OTT.S90602
24. Zhang Y, Wang R, Li Y, Pan Y, Hu H, Zhang Y, Li H, Shen L, Yu Y, Sun Y and Chen H: Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas. J Thorac Oncol 10(10): 1444-1450, 2015. PMID: 26200450. DOI: 10.1097/JTO.0000000000000626
25. Udupa KS, Rajendranath R, Sagar TG, Sundersingh S and Joseph T: Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting. Indian J Cancer 52(3): 266-268, 2015. PMID: 26905105. DOI: 10.4103/0019-509X.176693
26. Piljić Burazer M, Mladinov S, Ćapkun V, Kuret S and Glavina Durdov M: The utility of thyroid transcription factor 1 (TTF-1), Napsin A, excision repair cross-complementing 1 (ERCC1), anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) expression in small biopsy in prognosis of patients with lung adenocarcinoma – a retrograde single-center study from Croatia. Med Sci Monit 23: 489-497, 2017. PMID: 28128193. DOI: 10.12659/msm.899378
27. Nakra T, Singh V, Nambirajan A, Malik PS, Mohan A and Jain D: Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma. J Pathol Transl Med 55(4): 279-288, 2021. PMID: 34233113. DOI: 10.4132/jptm.2021.05.10
28. Han B, Yang L, Wang X and Yao L: Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. Onco Targets Ther 11: 2121-2129, 2018. PMID: 29695919. DOI: 10.2147/OTT.S157370
29. Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T and Katakami N: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC Cancer 18(1): 6, 2018. PMID: 29291705. DOI: 10.1186/s12885-017-3952-7
30. Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S and Taguchi A: SRGN-triggered aggressive and immunosuppressive phenotype in a subset of TTF-1-negative lung adenocarcinomas. J Natl Cancer Inst 114(2): 290-301, 2022. PMID: 34524427. DOI: 10.1093/jnci/djab183
31. Matsubara D, Yoshimoto T, Soda M, Amano Y, Kihara A, Funaki T, Ito T, Sakuma Y, Shibano T, Endo S, Hagiwara K, Ishikawa S, Fukayama M, Murakami Y, Mano H and Niki T: Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas. Cancer Sci 111(6): 2183-2195, 2020. PMID: 32237253. DOI: 10.1111/cas.14403